1. Wang, Feng, Zhao, Fen, Zhang, Li, Zhou, Yizhi, Yi, Junlin. 2022. CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma. In Molecular cancer, 21, 153. doi:10.1186/s12943-022-01623-8. https://pubmed.ncbi.nlm.nih.gov/35879762/
2. Cui, Jianfeng, Liu, Xiaochen, Shang, Qinghong, Shi, Benkang, Zou, Yongxin. 2024. Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance. In Molecular cancer, 23, 86. doi:10.1186/s12943-024-01996-y. https://pubmed.ncbi.nlm.nih.gov/38685067/
3. Lim, Nicholas, Townsend, Paul A. 2020. Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisation. In International journal of cancer, 147, 1528-1534. doi:10.1002/ijc.32900. https://pubmed.ncbi.nlm.nih.gov/32010971/
4. Chen, Shanshan, Zhang, Yongchao, Ding, Xiaoyan, Li, Wei. 2022. Identification of lncRNA/circRNA-miRNA-mRNA ceRNA Network as Biomarkers for Hepatocellular Carcinoma. In Frontiers in genetics, 13, 838869. doi:10.3389/fgene.2022.838869. https://pubmed.ncbi.nlm.nih.gov/35386284/
5. Borlado, Luis R, Méndez, Juan. 2007. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. In Carcinogenesis, 29, 237-43. doi:. https://pubmed.ncbi.nlm.nih.gov/18048387/
6. Zhao, H, Zhou, X, Yuan, G, Huang, B, Li, X. 2020. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme. In Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 23, 565-571. doi:10.1007/s12094-020-02449-w. https://pubmed.ncbi.nlm.nih.gov/32661826/
智鼠故事 
